



## Noxafil<sup>®</sup> (posaconazole) – First-time generic

- On August 30, 2019, [Lannett launched](#) Sinotherapeutics' [AB-rated](#) generic version of Merck's [Noxafil \(posaconazole\)](#) delayed-release tablets.
  - In addition, [Par launched](#) an authorized brand alternative of Noxafil tablets.
- Noxafil is approved for the prophylaxis of invasive *Aspergillus* and *Candida* infections.
- Noxafil is also available as a brand oral suspension and injectable solution.
  - The injection and solution carry the same indications as Noxafil tablets.
  - The oral solution is also approved for the treatment of oropharyngeal candidiasis including oropharyngeal candidiasis refractory to [itraconazole](#) and/or [fluconazole](#).
- According to IQVIA, Noxafil's annual U.S. sales as of June 2019 were \$325 million.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.